The lowdown on planning and communicating about RWE: an interview with Richard White

19 Nov 2021

Written by Richard White (Oxford PharmaGenesis)

Artificial intelligence and machine learning Comparative effectiveness research COVID-19 Interviews Methodology Real-world evidence

In this interview, expert panel member Richard White (Oxford PharmaGenesis, UK) discusses how to communicate real-world evidence (RWE) effectively, why ongoing moves to increase transparency are so important and some of the issues that need to be considered when utilizing real-world data (RWD) sources. Find out insights into how RWD and RWE communications will evolve in the next 5–10 years and how embedding RWD in randomized control trials (RCTs) can augment and streamline these trials. Please could you introduce yourself, your organization(s) and provide a summary of your career to date? I’m currently Chief Operating Officer at Oxford PharmaGenesis, a...